| PC-28465 |
Trastuzumab deruxtecan
HER2-targeting ADC
|
Trastuzumab deruxtecan (T-DXd, DS-8201a) is a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd) at a drug-to-antibody ratio (DAR) of 7-8, shows potent antitumor activity HER2-positive cancers. |